Norway-based clinical-stage biopharmaceutical company BerGenBio ASA (OSE: BGBIO) on Monday announced preliminary safety data from the Phase 1b portion of its BGBC016 study in first-line Non-Small Cell Lung Cancer (NSCLC) patients.
The study assessed three escalating doses of bemcentinib, a selective AXL kinase inhibitor, in combination with standard chemo-immunotherapy, doublet chemotherapy and pembrolizumab (Keytruda). The primary endpoint focused on safety, with results showing the combination was well tolerated across all doses with no new safety signals. No dose-related electrocardiographic changes (QTc) were observed.
Pharmacokinetic analyses confirmed adequate plasma exposure of bemcentinib, consistent with previous responder data from the BGBC008 study in second-line NSCLC patients. These findings support further development of bemcentinib in combination with chemo-immunotherapy for advanced NSCLC.
Genprex research collaborators to present positive data on Reqorsa Gene Therapy at SITC 2024
hVIVO reports positive results from RSV antiviral human challenge trial
BerGenBio reveals preliminary safety data from Phase 1b BGBC016 study in first-line NSCLC patients
Liquidia and Pharmosa expand collaboration for inhaled treprostinil
Alvotech launches confirmatory study for Entyvio biosimilar
Merck's KEYTRUDA receives new approvals in Japan for lung and urothelial cancers
Innate Pharma receives FDA clearance of IND for IPH4502, a Nectin-4 targeting ADC for solid tumours
Intas Pharmaceuticals reports positive opinion for HETRONIFLY in Europe
Insilico Medicine reveals positive preliminary results from ISM001-055Phase IIa clinical trial
NeoGenomics to present breakthrough data at ESMO 2024 on ctDNA and NGS for cancer diagnostics
OSE Immunotherapeutics initiates Phase 3 trial for cancer vaccine Tedopi
AbbVie advances solid tumour pipeline with new data at ESMO 2024
Amgen showcases promising data for IMDELLTRA in small cell lung cancer at WCLC 2024